Sharper Prostate MRI Scans May Not Mean Better Cancer Detection, Review Finds

One of the most consequential questions in modern prostate cancer diagnostics is deceptively simple: does a higher-quality magnetic resonance imaging scan actually translate into better detection of clinically significant prostate cancer? A new systematic review published in BMC Medical Imaging by radiologist Uğur Kesimal of Ankara Training and Research Hospital tackles this question head-on, and its conclusions are likely to unsettle assumptions held by many clinicians and imaging researchers. The review, which searched PubMed from its inception through 22 March 2026 using a reproducible Boolean strategy supplemented by backward reference screening, identified eighteen records, subjected twelve to full-text assessment, and ultimately included eight studies meeting the eligibility criteria. What emerged from that analysis is a picture of an evidence base that is sparse, methodologically fragmented, and far too inconsistent to support the confident claim that image quality drives diagnostic yield.

The central innovation of the review lies in how it framed its primary outcome. Rather than asking whether better scans improve overall diagnostic accuracy, the study standardized the outcome as the proportion of MRI-positive units, whether patients, lesions, or regions, that were subsequently confirmed to harbor clinically significant prostate cancer, abbreviated csPCa, on histopathology. This distinction matters enormously. Diagnostic accuracy metrics such as sensitivity and specificity depend on the full spectrum of examined patients, including those with negative scans, whereas the confirmation rate among MRI-positive findings speaks directly to the practical question that radiologists and urologists face every day: when a scan flags a suspicious area, how likely is that flag to correspond to genuinely dangerous cancer?

The technical core of the review is its careful handling of the unit of analysis, a methodological issue that has plagued the imaging literature for years. Studies reporting results at the patient level, the region level, and the lesion level are statistically non-interchangeable, because observations within the same patient are correlated and cannot simply be pooled as if they were independent. Recognizing this, the author refused to combine the extractable comparative data, which consisted of one patient-level study, one region-level study, and one lesion-level study, into a single meta-analytic estimate. Instead, findings were synthesized separately by unit of analysis, and risk of bias was assessed using QUADAS-2, the standard tool for evaluating the methodological quality of diagnostic accuracy studies. This conservative approach, while it limits the statistical power of the conclusions, protects readers from the false precision that arises when correlated observations are treated as independent data points.

The headline numbers from the three studies with extractable comparative counts are strikingly divergent. At the patient level, higher-quality MRI was associated with csPCa confirmation in 48.0 percent of MRI-positive patients, compared with 35.3 percent among lower-quality scans, yielding an unadjusted relative risk of 1.36 with a 95 percent confidence interval of 0.92 to 2.02, an interval that crosses the null value of one and therefore does not reach conventional statistical significance. At the region level, the corresponding figures were 56.1 percent versus 36.2 percent, a descriptive unadjusted relative risk of 1.55, suggesting a potentially meaningful advantage for higher-quality imaging when the analysis is anchored to anatomical zones rather than whole patients. Yet at the lesion level, the direction reversed entirely: 45.4 percent versus 48.0 percent, a descriptive relative risk of 0.95, implying essentially no benefit, and perhaps a trivial disadvantage, for higher-quality scans when individual suspicious lesions are the unit of comparison.

That reversal across units of analysis is the most intellectually provocative finding of the review, and it deserves careful interpretation. One plausible explanation is that patient-level analyses capture the cumulative benefit of image quality across the entire gland, including the detection of cancers that would otherwise be missed altogether, whereas lesion-level analyses condition on a suspicious finding already being present, thereby restricting the comparison to lesions visible under both quality conditions. In other words, a better scan may help radiologists find cancers that a poorer scan never flags at all, and this detection benefit is invisible when the analysis is restricted to lesions that both scans identified. Cluster-aware confidence intervals could not be derived for the region-level or lesion-level estimates because the underlying studies did not report the information needed to account for within-patient clustering, which means the precision of those descriptive ratios remains unknown.

Beyond the three quantitative comparisons, the wider evidence base included in the review painted a directionally inconsistent picture, with results shaped by selection bias, verification bias, and concerns about applicability. Selection bias arises when the population undergoing MRI is not representative of the clinical population at large, for example when only patients with elevated prostate-specific antigen levels or prior negative biopsies are imaged. Verification bias, arguably the most pernicious threat in this field, occurs when only MRI-positive patients undergo biopsy, leaving MRI-negative patients without a histopathological reference standard and thereby inflating apparent accuracy. Applicability concerns include differences in scanner hardware, field strength, acquisition protocols, and the scoring systems used to grade image quality, most notably PI-QUAL, the five-point quality score developed to standardize the assessment of prostate MRI examinations, alongside PI-RADS, the structured reporting system for suspicion of clinically significant cancer.

The review’s bottom-line conclusion is deliberately restrained. The available evidence does not establish that higher MRI quality improves overall PI-RADS diagnostic accuracy, and although some studies suggest higher csPCa confirmation among MRI-positive units when image quality is better, that signal rests on very-low certainty evidence by the standards used to grade confidence in medical research findings. The author explicitly calls for prospective multicenter studies with unit-consistent reporting and complete two-by-two data, the minimal tabular structure needed to compute sensitivity, specificity, and their confidence intervals without ambiguity. The absence of a prospectively registered review protocol is acknowledged as a limitation, a transparency concession that, while common in the imaging literature, underscores the field’s broader methodological immaturity on this specific question.

The clinical stakes of this uncertainty are considerable. Multiparametric MRI has become the gatekeeper of the prostate cancer diagnostic pathway in many health systems, used both to decide which men should undergo biopsy and to guide targeted sampling of suspicious lesions. If image quality genuinely modulates cancer yield, then quality assurance programs, scanner upgrades, and standardized quality scoring could deliver measurable reductions in missed clinically significant cancers and unnecessary biopsies alike. Conversely, if the association is weak or confined to particular units of analysis, then expensive investments in imaging infrastructure may yield diminishing returns, and attention may need to shift toward interpretation, biopsy technique, or risk-based patient selection. The current evidence, as this review makes clear, cannot yet adjudicate between those futures.

What the review does establish, with unusual methodological candor, is how much work remains before the field can speak with one voice. Eight studies spanning heterogeneous populations, differing quality thresholds, varied reference standards, and incompatible units of analysis constitute a foundation too narrow for firm clinical guidance. The standardized outcome adopted here, the proportion of MRI-positive units with histopathologically confirmed csPCa, offers a template for future research that could finally allow meaningful synthesis across centers and countries. Until such studies arrive, the review’s message to radiologists, urologists, and policymakers is one of disciplined humility: the intuition that sharper images find more dangerous cancers is plausible and partially supported, but it is not yet proven, and the patients whose treatment depends on that assumption deserve evidence of higher certainty than the field has so far produced.

Subject of Research: The association between prostate MRI image quality and histopathologically confirmed clinically significant prostate cancer in MRI-positive examinations

Article Title: MRI quality and csPCa confirmation in MRI-positive examinations

Article References: Kesimal, U. (2026). MRI quality and csPCa confirmation in MRI-positive examinations. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02918-8

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02918-8

Keywords: prostate cancer, multiparametric MRI, PI-RADS, PI-QUAL, image quality, csPCa, systematic review, diagnostic accuracy, radiology, biopsy, QUADAS-2, BMC Medical Imaging